A controlled study of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction.
Preliminary data obtained in the ambit of Anturan Reinfarction Italian Study (ARIS) show that, in postmyocardial infarction, reduced platelet survival time occurred in hyperbetalipoproteinemic patients treated with placebo, but not in the group of patients treated with sulfinpyrazone (interaction between treatment and lipemic level is at p approximately equal to 0.1). The sulfinpyrazone effect on platelet survival is probably related to the release reaction inhibition as suggested by our ex vivo results on platelet-bound 14C-serotonin release.
D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D010919:Placebos; D012008:Recurrence; D012701:Serotonin / Q000378:metabolism*; D013442:Sulfinpyrazone / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D008077:Lipoproteins, LDL; D010919:Placebos; D014280:Triglycerides; D012701:Serotonin; D002784:Cholesterol; D013442:Sulfinpyrazone